Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 24

1.

Phase II evaluation of sunitinib in the treatment of recurrent or refractory high-grade glioma or ependymoma in children: a children's Oncology Group Study ACNS1021.

Wetmore C, Daryani VM, Billups CA, Boyett JM, Leary S, Tanos R, Goldsmith KC, Stewart CF, Blaney SM, Gajjar A.

Cancer Med. 2016 Jul;5(7):1416-24. doi: 10.1002/cam4.713.

2.

Present Advances and Future Perspectives of Molecular Targeted Therapy for Osteosarcoma.

Shaikh AB, Li F, Li M, He B, He X, Chen G, Guo B, Li D, Jiang F, Dang L, Zheng S, Liang C, Liu J, Lu C, Liu B, Lu J, Wang L, Lu A, Zhang G.

Int J Mol Sci. 2016 Apr 6;17(4):506. doi: 10.3390/ijms17040506. Review.

3.

The Tyrosine Kinase Inhibitor Sunitinib Affects Ovulation but Not Ovarian Reserve in Mouse: A Preclinical Study.

Bernard V, Bouilly J, Kramer P, Carré N, Schlumberger M, Visser JA, Young J, Binart N.

PLoS One. 2016 Apr 1;11(4):e0152872. doi: 10.1371/journal.pone.0152872.

4.

Molecular profiling of childhood cancer: Biomarkers and novel therapies.

Saletta F, Wadham C, Ziegler DS, Marshall GM, Haber M, McCowage G, Norris MD, Byrne JA.

BBA Clin. 2014 Jun 28;1:59-77. doi: 10.1016/j.bbacli.2014.06.003. Review.

5.

Receptor tyrosine kinases: Characterisation, mechanism of action and therapeutic interests for bone cancers.

Ségaliny AI, Tellez-Gabriel M, Heymann MF, Heymann D.

J Bone Oncol. 2015 Jan 23;4(1):1-12. doi: 10.1016/j.jbo.2015.01.001. Review.

6.

Off-label use of targeted therapies in osteosarcomas: data from the French registry OUTC'S (Observatoire de l'Utilisation des Thérapies Ciblées dans les Sarcomes).

Penel-Page M, Ray-Coquard I, Larcade J, Girodet M, Bouclier L, Rogasik M, Corradini N, Entz-Werle N, Brugieres L, Domont J, Lervat C, Piperno-Neumann S, Pacquement H, Bay JO, Gentet JC, Thyss A, Chaigneau L, Narciso B, Cornille H, Blay JY, Marec-Bérard P.

BMC Cancer. 2015 Nov 5;15:854. doi: 10.1186/s12885-015-1894-5.

7.

Preclinical Evidence for the Use of Sunitinib Malate in the Treatment of Plexiform Neurofibromas.

Ferguson MJ, Rhodes SD, Jiang L, Li X, Yuan J, Yang X, Zhang S, Vakili ST, Territo P, Hutchins G, Yang FC, Ingram DA, Clapp DW, Chen S.

Pediatr Blood Cancer. 2016 Feb;63(2):206-13. doi: 10.1002/pbc.25763.

8.

Challenges of clinical trial design for targeted agents against pediatric leukemias.

Mussai FJ, Yap C, Mitchell C, Kearns P.

Front Oncol. 2015 Jan 6;4:374. doi: 10.3389/fonc.2014.00374. Review.

9.

Cardiovascular disease in adult survivors of childhood cancer.

Lipshultz SE, Franco VI, Miller TL, Colan SD, Sallan SE.

Annu Rev Med. 2015;66:161-76. doi: 10.1146/annurev-med-070213-054849. Review.

10.

Combining targeted agents with modern radiotherapy in soft tissue sarcomas.

Wong P, Houghton P, Kirsch DG, Finkelstein SE, Monjazeb AM, Xu-Welliver M, Dicker AP, Ahmed M, Vikram B, Teicher BA, Coleman CN, Machtay M, Curran WJ, Wang D.

J Natl Cancer Inst. 2014 Oct 18;106(11). pii: dju329. doi: 10.1093/jnci/dju329. Review.

11.

Growth plate abnormalities in pediatric cancer patients undergoing phase 1 anti-angiogenic therapy: a report from the Children's Oncology Group Phase I Consortium.

Voss SD, Glade-Bender J, Spunt SL, DuBois SG, Widemann BC, Park JR, Leary SE, Nelson MD, Adamson PC, Blaney SM, Weigel B.

Pediatr Blood Cancer. 2015 Jan;62(1):45-51. doi: 10.1002/pbc.25229.

12.

The angiogenic asset of soft tissue sarcomas: a new tool to discover new therapeutic targets.

Rocchi L, Caraffi S, Perris R, Mangieri D.

Biosci Rep. 2014 Nov 4;34(6):e00147. doi: 10.1042/BSR20140075. Review.

13.

Managing chemotherapy-related cardiotoxicity in survivors of childhood cancers.

Lipshultz SE, Diamond MB, Franco VI, Aggarwal S, Leger K, Santos MV, Sallan SE, Chow EJ.

Paediatr Drugs. 2014 Oct;16(5):373-89. doi: 10.1007/s40272-014-0085-1. Review.

14.

Circulating endothelial progenitor cells in castration resistant prostate cancer: a randomized, controlled, biomarker study.

Fuereder T, Wacheck V, Strommer S, Horak P, Gerschpacher M, Lamm W, Kivaranovic D, Krainer M.

PLoS One. 2014 Apr 22;9(4):e95310. doi: 10.1371/journal.pone.0095310.

15.

Targeted therapies for bone sarcomas.

Heymann D, Rédini F.

Bonekey Rep. 2013 Jul 17;2:378. doi: 10.1038/bonekey.2013.112.

16.

Phase I pharmacokinetic and pharmacodynamic study of pazopanib in children with soft tissue sarcoma and other refractory solid tumors: a children's oncology group phase I consortium report.

Glade Bender JL, Lee A, Reid JM, Baruchel S, Roberts T, Voss SD, Wu B, Ahern CH, Ingle AM, Harris P, Weigel BJ, Blaney SM.

J Clin Oncol. 2013 Aug 20;31(24):3034-43. doi: 10.1200/JCO.2012.47.0914.

17.

A review of targeted therapies evaluated by the pediatric preclinical testing program for osteosarcoma.

Sampson VB, Gorlick R, Kamara D, Anders Kolb E.

Front Oncol. 2013 May 31;3:132. doi: 10.3389/fonc.2013.00132.

18.

The combination of novel targeted molecular agents and radiation in the treatment of pediatric gliomas.

Dasgupta T, Haas-Kogan DA.

Front Oncol. 2013 May 10;3:110. doi: 10.3389/fonc.2013.00110.

19.

Bone sarcomas: from biology to targeted therapies.

Gaspar N, Di Giannatale A, Geoerger B, Redini F, Corradini N, Enz-Werle N, Tirode F, Marec-Berard P, Gentet JC, Laurence V, Piperno-Neumann S, Oberlin O, Brugieres L.

Sarcoma. 2012;2012:301975. doi: 10.1155/2012/301975.

20.

Ontogeny and sorafenib metabolism.

Zimmerman EI, Roberts JL, Li L, Finkelstein D, Gibson A, Chaudhry AS, Schuetz EG, Rubnitz JE, Inaba H, Baker SD.

Clin Cancer Res. 2012 Oct 15;18(20):5788-95. doi: 10.1158/1078-0432.CCR-12-1967.

Items per page

Supplemental Content

Support Center